The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / For Psoriasis, Ustekinumab & TNF Inhibitors Show Similar Cardiac Safety

For Psoriasis, Ustekinumab & TNF Inhibitors Show Similar Cardiac Safety

April 9, 2019 • By David Douglas

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—In patients with psoriasis and psoriatic arthritis, the incidence of atrial fibrillation and major adverse cardiovascular events does not differ between treatment with ustekinumab and TNF inhibitors, according to a large observational study.

You Might Also Like
  • TNF Inhibitor Tied to Lower Cardiovascular Risk in Psoriasis
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
Explore This Issue
May 2019

“Given a high cardiovascular risk among patients with psoriasis and psoriatic arthritis,” Seoyoung C. Kim, MD, ScD, MSCE, told Reuters Health by email, “it is important to understand the potential effect of different treatments on CV risk among these patients.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

And with an increasing number of systemic treatment options, she added, “there is a need for high-quality evidence on comparative safety of different systemic treatments including biologic drugs for a better medical decision making.”

Dr. Kim of Brigham and Women’s Hospital and Harvard Medical School, Boston, and colleagues examined insurance data from 2009 to 2015 involving more than 60,000 patients. Ustekinumab became available in the U.S. in 2009.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Nearly 51,000 patients received TNF inhibitors and 9,071 were given ustekinumab, the researchers report in JAMA Dermatology, online March 27.1 Mean follow-up was 1.4 years.

The overall crude incidence rate for atrial fibrillation per thousand patient-years was 4.7 for TNF inhibitors and 5.0 for ustekinumab. For major adverse cardiovascular events, the numbers were 6.1 and 6.2, respectively.

Compared with TNF inhibitors, the combined adjusted hazard ratios for incident atrial fibrillation and major adverse cardiovascular events among ustekinumab initiators were 1.08 and 1.10, respectively, neither of which was statistically significant.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Furthermore,” the researchers write, “these risks did not appear to substantially differ across the subgroups included in our study.”

The researchers called for further research in subgroups, but concluded “the current study provides [cardiovascular] safety data from an important head-to-head comparison (two most commonly used categories of biologic drugs for the conditions) in a real-world setting.”

Robert T. Brodell, MD, chair of the department of dermatology at the University of Mississippi Medical Center, Jackson, tells Reuters Health by email, “As with any new drugs, physicians are always worried about benefits and risks. The biologics used in treating psoriasis, as a class have proven to be very safe, especially when compared to the drugs with used systemically for psoriasis in the pre-biologic era (methotrexate, cyclosporine and acitretin).”

Dr. Brodell, who was not involved in the study, adds that there are indications that major adverse cardiovascular events and atrial fibrillation may be related to certain biologic drugs. Thus, “it is comforting to know that ustekinumab and anti-TNF drugs have the same low risks of these side effects.”

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: cardiovascular, cardiovascular event, Psoratic Arthritis, Psoriasis, Safety, TNF inhibitor, ustekinumabIssue: May 2019

You Might Also Like:
  • TNF Inhibitor Tied to Lower Cardiovascular Risk in Psoriasis
  • Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk
  • TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.